Spinal Cord Injury Investment Symposium: The Co-Founder and CEO of NeuroHagana discusses the role that glutamate excitotoxicity plays in neurotrama injury

blonca9
Jun 27, 2024
1 min read

Angela Ruban describes how NeuroHagana is developing a treatment to lower blood glutamate levels that she believes would ideally be administered as quickly after acute injury as possible.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Spinal Cord Injury Investment Symposium: The Co-Founder and CEO of NeuroHagana discusses the role that glutamate excitotoxicity plays in neurotrama injury

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight